Answers are grounded in this paper and cite their sources.
Three pediatric oncology patients received isavuconazole concurrently with vincristine across 15 days to approximately 23 months, spanning 32 vincristine doses. No severe adverse effect including neurotoxicity or paralytic ileus was attributed to the combination.
No takes yet. Share an insight, caveat, or question.
Shieb et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: